Prognostic Factors in Adolescent and Adult Patients With Acute Lymphoblastic Leukemia With Two Protocols of Chemotherapy: A Cross-Sectional Study

Micro-Abstract Data about Adult Acute lymphoblastic leukemia treatment in South America population is scarce. 88 patients were treated with BFM86 modified or UCLA protocols. The median follow up was 49 months, the overall survival (OS) was 30.5%. Age less than 35y was associated to better OS and in...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia Vol. 15; no. 1; pp. e7 - e14
Main Authors:	Pinheiro Junior, Edilson Diogenes, Pracchia, Luis Fernando, Beitler de Mauriño, Beatriz, Martinez, Gracia Aparecida, Dorlhiac-Llacer, Pedro Enrique, Medina, Andrezza Bertolaci, Velloso, Elvira Deolinda Rodrigues Pereira
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 2015
Subjects:	Acute leukemia Acute lymphoblastic leukemia Adolescent Adult Antineoplastic combined chemotherapy protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asparaginase - therapeutic use Child Consolidation Chemotherapy Cross-Sectional Studies Cyclophosphamide - therapeutic use Cytarabine - therapeutic use Drug therapy Female Hematology, Oncology and Palliative Medicine Humans Induction Chemotherapy Male Mercaptopurine - therapeutic use Methotrexate - therapeutic use Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Prednisone - therapeutic use Prognosis Retrospective Studies Survival Treatment Outcome Vincristine - therapeutic use Young Adult Acute leukemia Antineoplastic combined chemotherapy protocols Prognosis Acute lymphoblastic leukemia Drug therapy Survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Micro-Abstract Data about Adult Acute lymphoblastic leukemia treatment in South America population is scarce. 88 patients were treated with BFM86 modified or UCLA protocols. The median follow up was 49 months, the overall survival (OS) was 30.5%. Age less than 35y was associated to better OS and in young patients with no other adverse factor, BFM 86m treatment arm was superior.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2014.07.006